Miscellaneous
Cardiac Findings After Enzyme Replacement Therapy for Mucopolysaccharidosis Type I

https://doi.org/10.1016/j.amjcard.2006.02.047Get rights and content

Mucopolysaccharidosis type I is a lethal autosomal recessive storage disease caused by a deficiency of lysosomal α-l-iduronidase and the consequent systemic accumulation of glycosaminoglycan. Cardiomyopathy and valvar insufficiency occur as glycosaminoglycan accumulates in the myocardium, expands the spongiosa of cardiac valves, and proliferates within the myointima of the epicardial coronary arteries. Congestive heart failure and death occur within the first decade of life in the most severe cases. Allogeneic hematopoietic stem cell transplantation, used in severe forms of the disease, markedly prolongs survival, alleviates ventricular hypertrophy, and preserves cardiac function, but cardiac valves continue to thicken and valvular insufficiency progresses. Enzyme replacement therapy with human recombinant α-l-iduronidase has been proposed as an alternativee therapy for patients with mucopolysaccharidosis type I in whom the risk/benefit ratio of hematopoietic stem cell transplantation seems unfavorable. The investigators report the cardiac findings in a small series of 5 children with mucopolysaccharidosis type I who received enzyme replacement therapy for as long as 7 years. No deaths occurred during treatment. Left ventricular hypertrophy, which was present before therapy, resolved in all cases, and myocardial function remained normal. In contrast, the mitral and aortic valves remained thickened and, in some instances, developed progressive thickening and regurgitation. In conclusion, long-term enzyme replacement therapy has some clear benefits for the myocardium, but the cardiac valves appear unresponsive, and the ultimate effect on the coronary vasculature is unknown.

Cited by (100)

  • Identification of a novel fusion Iduronidase with improved activity in the cardiovascular system

    2022, Molecular Genetics and Metabolism Reports
    Citation Excerpt :

    In particular, cardiac valvular disease is common in mucopolysaccharidosis type I (MPS I), type II (MPS II), and type VI (MPS VI) [5–12]. While HCT and ERT are therapeutic options for some MPS diseases, HCT and ERT do not treat all cardiovascular complications, specifically cardiac valvular disease [5,13–23]. While the exact reasoning is unclear, the limited benefits of HCT and ERT on cardiac valves is thought to be due to the poor vascularization of cardiac valves [5].

  • The factors affecting lipid profile in adult patients with Mucopolysaccharidosis

    2017, Molecular Genetics and Metabolism Reports
    Citation Excerpt :

    Haematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT) have changed the previously life-limiting natural history of the MPSs and improved their survival well into adulthood. Although the positive effect of HSCT and ERT on ventricular function, with no effect on cardiac valve pathology, has been previously recognized [24,25,26,27], little is known about hyperlipidaemia as a potential cardiovascular risk factor in this cohort of patient. Baseline cholesterol data in adults are scarce, reported only for MPS I [28] where it was found to be normal.

View all citing articles on Scopus
View full text